Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure (Q73445145)
Jump to navigation
Jump to search
scientific article published on 01 February 2000
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure |
scientific article published on 01 February 2000 |
Statements
Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure (English)
1 February 2000